SCHEMBL4308121

SCHEMBL4308121

O=C(O)CNC(=O)c1nc2cc(-c3cnc4ccccc4c3)ccc2[nH]1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 9/20 0.52
EGLN3 Q9H6Z9 3/20 0.52
FTO Q9C0B1 2/20 0.52
F9 P00740 1/20 0.43
MAP4K4 O95819 1/20 0.42
CSNK1G2 P78368 1/20 0.42
CLK4 Q9HAZ1 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
MAP4K5 Q9Y4K4 1/20 0.42
KDM4C Q9H3R0 1/20 0.42
DYRK1A Q13627 1/20 0.41
NTSR1 P30989 3/20 0.41
PIK3CD O00329 1/20 0.40
PIK3CA P42336 1/20 0.40
TET3 O43151 1/20 0.40
BBOX1 O75936 1/20 0.40
VEGFA P15692 1/20 0.40
FLT1 P17948 1/20 0.40
ASPH Q12797 1/20 0.40
TET2 Q6N021 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4313112 0.88 EGLN1 (0.57) EGLN1EGLN3FTOKDM4CHIF1AN
SCHEMBL4307002 0.81 EGLN1 (0.57) EGLN1FTOBBOX1ASPHKDM8
SCHEMBL17154106 0.79 EGLN1 (0.55) EGLN1
SCHEMBL4310730 0.79 EGLN1 (0.65) EGLN1EGLN3FTOKDM4CHIF1AN
SCHEMBL4307360 0.79 EGLN1 (0.67) EGLN1CLK4KDM4C
SCHEMBL4303435 0.77 EGLN1 (0.65) EGLN1EGLN3VEGFAFLT1
SCHEMBL4313430 0.77 EGLN1 (0.67) EGLN1
SCHEMBL4303188 0.76 EGLN1 (0.52) EGLN1EGLN3FTOF9TET3
SCHEMBL4310690 0.76 CNR2 (0.46) EGLN1EGLN3FTOF9
SCHEMBL13625773 0.76 FAAH (0.51) EGLN1F9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150284335-A1 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 US claimed
WO-2009134754-A1 BENZOIMIDAZOLE GLYCINAMIDES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-11-05 WO claimed
US-20150284335-A1 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 US disclosed
US-20150284335-A1 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 US disclosed
US-20150284335-A1 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 US disclosed
WO-2009134754-A1 BENZOIMIDAZOLE GLYCINAMIDES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284335-A1 Benzoimidazoles as prolyl hydroxylase inhibitors EGLN3, EGLN2, P4HA1 EGLN1 5/4885EGLN3 1/4885FTO 2056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.